UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  March 10, 2009

 

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

4575 SW Research Way, Suite 200

Corvallis, OR 97333

(Address of principal executive offices)

 

(541) 753-3635

Registrant’s telephone number, including area code

 

1 S.W. Columbia, Suite 1105

Portland, OR 97258

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 2.02.  Results of Operations and Financial Condition.

 

On March 10, 2009, AVI BioPharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth fiscal quarter and fiscal year ended December 31, 2008.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02, in Item 9.01 hereof and in Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01.  Financial Statements and Exhibits.

 

The following exhibit is being furnished (not filed) herewith:

 

99.1

Press release, dated March 10, 2009, entitled “AVI BioPharma Announces Fourth Quarter and Year End 2008 Financial Results”

 

2

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Corvallis, State of Oregon, on March 10, 2009.

 

		AVI BioPharma, Inc.
		By:	/s/ Leslie Hudson, Ph.D.
			Leslie Hudson, Ph.D.
			President and Chief Executive Officer (Principal Operating Officer)

 

3

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release, dated March 10, 2009, entitled “AVI BioPharma Announces Fourth Quarter and Year End 2008 Financial Results”

 

4